Trial Profile
An international collaborative study to discontinue Imatinib/Glivec in pediatric CML patients with sustained complete molecular response
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Protein tyrosine kinase inhibitors
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms STOPIMAPED
- 10 Apr 2023 Status changed from recruiting to discontinued.
- 01 Dec 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-006239-44).
- 02 Oct 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.